Endocrine Abstracts

According to the 4th edition of the WHO classification of endocrine organ tumors (2017), all pheochromocytomas are classified as malignant tumors (ICD-O code 8700/3). However, in the literature there are no unambiguous data on the significance of clinical and laboratory predictors of the aggressiveness of pheochromocytoma. The aim of the study was to verify possible predictors of pheo-progression using clinical data, the results of laboratory and instrumental examination (incl...

Adrenocortical cancer (ACC) is a tumor of the adrenal cortex, clinical manifestations, recurrence, and progression potential are determined by its biological characteristics. Morphological diagnosis of tumors of the adrenal glands in some cases presents significant difficulties. According to the WHO classification of tumors of the endocrine organs (4th revision, 2017), in addition to the classical one, myxoid, sarcomatoid and oncocytic histological variants of ACC are distingu...

Neuroendocrine neoplasias (NENs) are a heterogeneous group of tumors that differ in appearance, growth patterns, and clinical symptoms and develop from neuroendocrine cells and, accordingly, unusually similar cytological characteristics. Pheochromocytoma is considered as not epithelial type of NENs. We would like to present a clinical case of pheochromocytoma with difficulties in laboratory diagnosis and morphological verification. Female patient P., 60 years old, for 10 years...

A 31-year-old female patient without previous history of pituitary diseases, at 16 weeks of 4th spontaneous pregnancy complained about severe headache; diplopia and right ptosis developed shortly, nausea and vomiting appeared. Brain MRI showed the mass lesion 30×19×14 mm (frontal×vertical×sagittal) with supra-laterosellar extension, deforming and displacing optic chiasm; signs of pansinusitis, pathological contents of the right mastoid cells, vascular malfo...

Introduction: Previous studies demonstrated a relationship between T1- and T2-weighted signal intensity and tumor growth pattern in pituitary somatotropinomas. The goal of this retrospective study was to analyze the MRI characteristics of pituitary macroadenomas with different hormonal activity in newly diagnosed patients.Material and methods: Pre-treatment T1- and T2-weighted MR-images (Intera Achieva, PHILIPS, 3.0T) of patients with 42 non-functional a...

Prevalence of macroprolactin in serum (>40%) can be a cause of asymptomatic hyperprolactinemia. However, there is still lack of evidence how to manage with symptomatic patients with macroprolactinemia.We analyzed clinical data and monomeric prolactin levels in 85 women of reproductive age with hyperprolactinemia: NonTumor hyperprolactinemia (NT, n=31), MIcroadenomas (MI, n=32), MAcroadenomas (MA, n=22). Prolactin levels 171...

Our Pituitary Tumour Registry includes data about 346 patients with pituitary macroadenomas: 142 non-functional adenomas (NFA) including 18 (12.7%) giant, 62 macroprolactinomas – 6 (9.7%) giant, 141 somatotropinomas – 6 (4.3%) giant. We analysed clinical features of these 30 giant pituitary tumors (<40 mm at least one of the sizes): 18 NFA (11 Females; 7 Males), 6 prolactinomas (3 Females; 3 Males), 6 somatotropinomas (3 Females; 3 Males). Patients with giant NFA...

There are some data concerning high prevalence of infrasellar extension of somatotropinomas. To reveal any differences expansion of pitutary macroadenomas with various hormonal secretion, we have analyzed MRI data of 175 pituitary macroadenomas: 87 non-functioning adenomas (NFAs), 48 prolactinomas, 43 somatotropinomas. The sizes of pituitary tumour (vertical, sagittal, frontal): NFAs 24 (17.5; 34.5)mm, 23 (17.4; 28) mm, 23 (18; 30) mm; prolactinomas 21 (15; 31) mm, 20 (16; 30)...

We analysed BMI of 270 female patients: 148 with hyperprolactinaemia (non-tumoural hyperprolactinaemia, n=46; microadenomas, n=56; and macroadenomas, n=46), 55 with isolated central hypogonadism, 67 with hypopituitarism. Additionally, 53 healthy women of reproductive age and 51 postmenopausal women were examined. In patients with hyperprolactinaemia median prolactin levels were 1547 (1124; 2185), 1490 (1050; 2280), and 3100 (1790; 18840) mE/l, accord...

We investigated 49 patients with non-functioning pituitary macroadenomas: 11 males, 38 females, age 31–78 y.o. (median 61). Extrasellar tumor expansion was observed in 46 (93.9%) patients: suprasellar – 41 (83.7%), laterosellar 27 (55.1%), and infrasellar 18 (36.7%) patients; combined types of extrasellar expansion – 36 (73.5%) patients.Prolactin levels (PRL) varied from 115 to 1495 mU/l, hyperprolactinemia was found in 27 (55.1%) patients...